Previous 10 | Next 10 |
Beasley Broadcast Group (BBGI) +54% on Q3 results.Alaska Communications Systems Group (ALSK) +56% after announcing agreement to be acquired by Macquarie Capital and GCM Grosvenor for $3.0 per share.JAKKS Pacific (JAKK) +18% on Q3 results.trivago N.V. (TRVG) +15%....
Humanigen (HGEN) perks 7% premarket after executing its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. and KPM Tech Co., Ltd for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines. ...
Agreement provides Humanigen up to US$20 million in milestones and double-digit royalties on product sales Transaction supports the Humanigen Asia-Pacific regional corporate development strategy Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”),...
Humanigen starts dosing patients in Phase 3 COVID-19 vaccine trial. AbbVie reports positive topline data for AGN-190584 Phase 3 trial. ChemoCentryx reports Phase II AURORA data for Avacopan. For further details see: Humanigen Dosing Phase 3 Covid Patients, And Othe...
The following slide deck was published by Humanigen, Inc. in conjunction with this event. For further details see: Humanigen (HGEN) Investor Presentation - Slideshow
Humanigen ([[HGEN]] +6.4%) has announced treatment of its first COVID-19 patient with lenzilumab in Phase 3 trial, at MedStar Washington Hospital Center, one of 18 sites in the U.S. approved to enroll eligible patients to study lenzilumab, designed specifically to cyt...
New study site actively enrolling eligible hospitalized patients with COVID-19 in clinical trial in Washington, D.C. Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-...
The first participant has been dosed in an NIAID-sponsored 200-subject Phase 2 proof-of-concept clinical trial, ACTIV-5/BET-B, evaluating Humanigen's (HGEN) lenzilumab, combined with Gilead Sciences' (GILD) Veklury (remdesivir), in hospitalized adult COVID-19 patients.The primary endpoint is ...
First patient dosed at the Emory University School of Medicine in Atlanta, Georgia Trial will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in up to 200 patients hospitalized with COVID-19 Humanigen, Inc. , (Nasdaq: HGEN) ...
Socket Mobile (SCKT) +42% as its S550 contactless reader achieves Apple wallet compatibility.AgeX Therapeutics (AGE) +16%.First Solar (FSLR) +12% on Q3 results.Tupperware Brands (TUP) +11% on Q3 results.Scholar Rock Holding (SRRK) +10%.XpresSpa Group (XSPA)&...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...